Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

NCT04633811 · View on ClinicalTrials.gov ↗

Study Summary

This protocol seeks to determine if weight reduction with the Optifast VLCD program leads to reduced contribution of endogenous oxalate synthesis and dietary oxalate absorption to the urinary oxalate pool in obese calcium oxalate stone formers.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Low Oxalate Diet before Weight Loss
  • DIETARY_SUPPLEMENT Oral load of oxalate and sucralose before Weight Loss
  • DIETARY_SUPPLEMENT Optifast VLCD Program
  • DIETARY_SUPPLEMENT Optifast VLCD Transition Phase
  • DIETARY_SUPPLEMENT Low Oxalate Diet after Weight Loss

Study Locations (1)

Alabama

  • University of Alabama at Birmingham — Birmingham

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2021-12-03
Est. Completion 2026-12-31
Phase NA

Sponsor

University of Alabama at Birmingham

1,315 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04633811

The ClinicalTrials.gov registry entry for NCT04633811 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,315 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Kidney Stone appearing as the primary indexed condition, and to 5 interventions — of which Low Oxalate Diet before Weight Loss is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04633811 reports 1 study location spanning 1 distinct geographic area — top geographies include Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04633811 about?

NCT04633811 is a clinical study titled "Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers". This protocol seeks to determine if weight reduction with the Optifast VLCD program leads to reduced contribution of endogenous oxalate synthesis and dietary oxalate absorption to the urinary oxalate pool in obese calcium oxalate stone formers.

What is the current status of trial NCT04633811?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 14 participants. The study started on 2021-12-03. Estimated completion is 2026-12-31.

What conditions does trial NCT04633811 study?

This clinical trial studies the following conditions: Kidney Stone. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04633811?

The interventions under investigation include: Low Oxalate Diet before Weight Loss (DIETARY_SUPPLEMENT), Oral load of oxalate and sucralose before Weight Loss (DIETARY_SUPPLEMENT), Optifast VLCD Program (DIETARY_SUPPLEMENT), Optifast VLCD Transition Phase (DIETARY_SUPPLEMENT), Low Oxalate Diet after Weight Loss (DIETARY_SUPPLEMENT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04633811?

This trial is sponsored by University of Alabama at Birmingham, which has 1,315 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04633811 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial